News Digest / Ticker: CAMX

Ticker: CAMX

04:06am, Thursday, Jun 11, 2026

Camurus Shares Drop 7% Following FDA Rejection of Acromegaly Therapy

Shares of Camurus slid 7% after the FDA declined approval for its acromegaly drug Oclaiz, citing manufacturing and labeling issues, delaying launch to 2027 without raising safety or efficacy concerns.